header logo image


Page 19«..10..18192021..3040..»

Archive for the ‘Arthritis’ Category

Nightshades and arthritis are often connected – The Durango Herald

Tuesday, September 15th, 2020

This is the time of year when fresh produce is at its peak.

The farmers markets and grocery stores are an abundance of natures glory. Fruit is literally falling off the trees. Home gardens are bursting with joyful rewards of months of labor and love.

Its also a time of year when I see more arthritis patients joints seem to be acting up or more troublesome. Folks often attribute this to using their hands more in the garden, painting projects, etc. Sometimes over-work is absolutely the culprit. And sometimes it can be tied back to eating an abundance of garden booty salsa, green chile, gazpacho or tomatoes warm from the vine.

What do these foods have in common? They are part of the nightshade, or Solanaceae, family. This group of foods is high in glycoalkaloids, especially solanine. It is theorized that these glycoalkaloids can be pro-inflammatory in some people and could be a contributor to arthritic pain. This class of foods includes potatoes, tomatoes, all peppers, eggplant, tomatillos, paprika and cayenne. The nightshade family does not include sweet potatoes, yams or black pepper.

The easiest way to know if these are foods that are causing more pain in your joints is simply to cut them out for 3-4 weeks completely. This is one of the hardest recommendations I make in my practice because this time of year the nightshade foods are so delicious! Veggies in the nightshade family are also high in nutrients, especially vitamins C and A. However, both osteoarthritis and rheumatoid arthritis can be debilitating and neither have great Western medical interventions available. The treatments that are offered often carry their own concerning side effects.

Adjusting your diet to see if certain foods are impacting you is a great way to take your health into your own hands. It doesnt require any testing and is free! There are a couple simple guidelines that can help this be more successful for you. The first is to be diligent and not cheat. You must strictly eliminate the foods in question for at least 3 weeks no exception, otherwise youll never know for sure. Choose a time frame that works for you having start and end dates are essential. (It helps to know theres a light at the end of the tunnel!) Look at your calendar and plan for what you might do if you have events scheduled. Take some time to clear out the foods youre avoiding from your kitchen and think about what you might eat instead. For example, if you love pasta, pesto would be a great alternative to red sauce. Take time each day to record the severity of your symptoms. It is impossible to remember what your pain was like 2 weeks ago and can be helpful to notice if it dropped from a 7 to a 4, as opposed to saying it still hurts.

Finally, connect with your deeper why. If you didnt have joint pain, what would that create in your life? Write that down and keep it on your fridge, in your car and your bathroom to keep you inspired about whats really important.

Remember, not everyone will have this reaction to nightshades. And if you notice that they impact you, play with those foods in moderation. You can also just eat one of the foods (like peppers) and see how that feels in your body it might be that a particular food within the group is more of an issue. Either way, youll be more connected to you.

Nicola Dehlinger is a naturopathic doctor at Pura Vida Natural Healthcare in Durango. She can be reached at 426-1684 or http://www.puravidahealthcare.com.

Continue reading here:
Nightshades and arthritis are often connected - The Durango Herald

Read More...

Psoriatic Arthritis-Friendly Weight Loss Tips – Everyday Health

Tuesday, September 15th, 2020

Maintaining a healthy weight plays an important role in managing psoriatic arthritis. Obesity causes low-grade inflammation, as fat tissue churns out inflammatory proteins, including cytokines, chemokines, and adipokines. Being overweight or obese has been linked to an increased risk of developing psoriatic arthritis, an inflammatory condition, and making it more difficult to manage.

Excess weight puts more pressure on your joints, which can lead to injury and inflammation. Whats more, excess weight can interfere with medications that treat psoriatic arthritis, so they dont work as well. A review published in May 2018 in the journal PLoS ONE found that obesity was linked to a 60 percent greater chance that a class of biologic drugs commonly used to treat psoriatic arthritis, called tumor necrosis factor (TNF) inhibitors, wouldnt work.

The link between obesity and psoriatic arthritis is very complex and not adequately understood, says John Davis, III, MD, a clinical rheumatologist who specializes in psoriatic arthritis at Mayo Clinic in Rochester, Minnesota. We believe that [obesity] drives inflammation, providing the link to the joint disease.

Psoriatic arthritis is also linked to other health conditions, such as heart disease, diabetes, and metabolic syndrome. For all of these, Losing weight and maintaining weight in a healthy range is important, says Melissa Ann Prest, DCN, RDN, a spokesperson for the Academy of Nutrition and Dietetics.

The good news: Weight loss has been linked to an improvement in psoriatic arthritis symptoms, including painful, swollen joints and fatigue. Its probably reducing the inflammatory burden, says Dr. Davis.

American College of Rheumatology and National Psoriasis Foundation (NPF) guidelines, published in November 2018 in the journal Arthritis & Rheumatology, recommend weight loss for all obese people who have psoriatic arthritis to help improve their response to medication. Losing weight helps psoriatic arthritis symptoms in other ways, as well, explains Rajat Bhatt, MD, a rheumatologist with Memorial Hermann Health System in Texas. It decreases inflammation and stress on the joints and lowers uric acid levels linked to gout another joint condition common in people who have psoriatic arthritis.

And weight loss doesnt have to be major. Research has found that overweight and obese people with psoriatic arthritis who lost just 5 percent of their body weight were more likely to have minimal disease activity.

Although psoriatic arthritis symptoms such as fatigue and stiff, achy joints can make it more challenging to move, its possible to drop extra pounds with the right strategies and support. Here are a some tips to help you lose weight and improve your symptoms.

Daviss number one tip for weight loss in people who have psoriatic arthritis is to eliminate added sugars. They provide extra calories that dont benefit your body and can increase chronic inflammation, upping your risk of related conditions, such as obesity and diabetes.

Another reason to cut back on sugar: A review published in April 2020 in the journal Rheumatology and Therapy found that people who have psoriatic arthritis are significantly more likely to have type 2 diabetes than the population at large, possibly because inflammation of the skin and joints may affect glucose metabolism. Davis recommends limiting simple sugars and carbohydrates in your diet. Sugar hides in processed foods, cereal, yogurts, and juices, he says.

The NPF also recommends cutting out the following:

Foods from these sources are typically going to be higher in calories and trans fat, which can contribute to weight gain and inflammation, says Dr. Prest.Because cutting out these foods helps reduce inflammation, which worsens psoriatic arthritis, it may also help reduce psoriatic arthritis symptoms, explains Dr. Bhatt.

Research suggests that eating lots of fruits and vegetables can help you lose weight by keeping you full and satisfied on fewer calories, according to the Centers for Disease Control and Prevention (CDC). People should definitely eat more fruits and veggies, adds Davis.

A plant-based diet can also help decrease inflammation levels, which may reduce psoriatic arthritis symptoms, adds Bhatt. He specifically recommends the Mediterranean diet, which is rich in anti-inflammatory omega-3 fatty acids.

Dietary guidelines from the medical board of the NPF published in August 2018 in JAMA Dermatology, also recommend a Mediterranean diet, consisting of at least:

Make vegetables the star of your meal by filling half of your plate with non-starchy vegetables, and go with a serving of fruit or a serving of a vegetable for snacks, says Prest.

Its easy to confuse thirst for hunger, according to the NPF. So be sure to drink enough water to help with your weight loss efforts. About eight 8-ounce glasses per day is a good goal, according to the Mayo Clinic. Youll know youre hydrated if your urine is clear to light yellow.

Physical activity helps reduce inflammation and pain. Weight loss guidelines from the CDC recommend at least 150 minutes of moderate physical activity per week. Exercise is great for your overall health and to break through those weight loss plateaus, says Prest.

Staying physically active is especially important for people who have psoriatic arthritis, as metabolic syndrome has been linked to psoriatic arthritis disease activity and medication effectiveness, says Bhatt. Exercise can help you tackle metabolic syndrome by reducing inflammation and improving muscular metabolism. And thats not all. Exercise can increase range of motion in the joints and maintain joint flexibility and muscle strength, says Bhatt. Physical activity also increases pain tolerance, helping psoriatic arthritis symptoms feel less debilitating, and decreases uric acid, which reduces joint pain in people who also have gout, he adds.

If youre experiencing a lot of joint pain in your lower extremities, Bhatt recommends swimming a few laps. Swimming is a good low-impact activity for those who have access to a pool and enjoy it, says Davis.

Walking is a great exercise for people with psoriatic arthritis to lose weight, says Davis. Maintaining daily activity and step counts [helps] to increase metabolism, he says. When combined with dietary changes, walking supports weight loss, according to the Mayo Clinic, and is especially important for weight loss maintenance.

A study published in December 2018 in the journal BioMed Research International suggests that weight-bearing aerobic exercises, such as walking, may help reduce the risk of bone loss. Thats important, as another study, published in July 2020 in Annals of the Rheumatic Diseases, suggests that psoriatic arthritis treatments may increase the risk of osteoporosis.

If you need extra motivation, use a fitness tracker to track your steps. Set small, manageable goals that slightly challenge you. And listen to your body: Its natural to feel a bit sore or tired the next day, but take it easy if you feel pain.

Once your routine is no longer challenging, consider increasing the intensity. The body always has to be challenged. Choose something you like, so you can stick to a long-term plan, says Bhatt.

Resistance training, which includes weight lifting and body weight exercises, such as squats, can help with both weight loss and overall fitness. One small study published in February 2018 in the journal Clinical Rheumatology found that people with psoriatic arthritis who did resistance training twice a week for 12 weeks reduced their disease activity and pain and improved their quality of life.

Whats more, building muscle helps with weight loss. Thats because muscle burns more calories than fat does, even at rest, according to the Mayo Clinic. Lifting weights may be even more important when youre cutting back on calories, because your body sheds some muscle mass along with fat when you lose weight. The CDCs weight loss guidelines recommend incorporating strength-training activities that use all the major muscle groups two days a week.

If joint pain makes this kind of exercise challenging, ask your doctor for tips on how to get started safely.

The dietary guidelines from the NPF recommend a reduced-calorie diet for people with psoriatic arthritis who are obese. Talk to your doctor to determine the right goal for you. Tracking your calorie intake can be especially helpful. Studies show that just keeping a simple food journal reduces intake, because it makes you more aware of what youre eating and helps you figure out a better choice, says Prest.A study published in February 2019 in the journal Obesity followed 142 people on their weight loss journey for 24 weeks and found that those who more often used an online food journal reported more weight loss after six months.

I have used the photo journal technique with many clients, and they have had great success in reaching their weight loss goals, says Prest. Free apps and online tracking tools also give you a great estimate of your overall diet, but keep in mind theyre not 100 percent accurate, she adds.

A lack of sleep is linked to impairments in glucose metabolism and an increased risk of type 2 diabetes, metabolic changes, and inflammation, according to a review published in March 2015 in the journal Diabetology and Metabolic Syndrome. This can affect not only your weight loss efforts but also your overall health, including psoriatic arthritis symptoms.

A good nights sleep helps with pain sensitization and improves pain tolerance, and therefore, psoriatic arthritis symptoms might be better, says Bhatt. When the body rests, it rids itself of toxins, which helps improve inflammation. And good sleep helps with weight loss. Davis suggests people with psoriatic arthritis aim for at least 7 to 8 hours of sleep each night.

A study published in October 2018 in the journal Reumatologia suggests that many people who have psoriatic arthritis have trouble sleeping. A few of Bhatts top sleep hygiene tips:

If [youre] struggling, seeing a dietitian is a good idea, says Davis. A dietitian can help you develop a customized meal plan, which can be especially helpful for people who have psoriatic arthritis. People with psoriatic arthritis may find that they have other food sensitivity issues that may contribute to problems with weight loss. Working with a registered dietitian nutritionist is a great way to ensure youre eating the right amount for weight loss, says Prest. You can search for a registered dietitian nutritionist near you at eatright.org.

If youre struggling with exercise, a physical therapist or personal trainer can develop a fitness routine suited to your needs.

Finally, keep at it, because even small changes can be powerful. We often overemphasize pharmaceutical therapies and underemphasize lifestyle changes, says Bhatt, but lifestyle changes are equally important for all arthritis patients.

Link:
Psoriatic Arthritis-Friendly Weight Loss Tips - Everyday Health

Read More...

Arthritis Market Expected to Witness High Growth over the Forecast Period 2019 2026 – Kewaskum Statesman News Journal

Tuesday, September 15th, 2020

Data Bridge Market Research has recently published the Global research Report TitledArthritis Market. The study provides an overview of current statistics and future predictions of the Global Arthritis Market.The study highlights a detailed assessment of the Market and displays market sizing trends by revenue & volume (if applicable), current growth factors, expert opinions, facts, and industry validated market development data.

Global arthritis market is expected to register a substantial CAGR in the forecast period of 2019-2026. The report contains data from the base year of 2018 and the historic year of 2017. This rise in market value can be attributed to the increasing awareness regarding the disease and the modes of its treatment.

Access Insightful Study With Over 100+ Pages, List Of Tables & Figures, Profiling 10+ Companies. Ask For Free Sample Copy Of Arthritis Market Report:https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-arthritis-market&utm_source=&kA

The report gives explanations about market definition, currency and pricing, market segmentation, market overview, premium insights, key insights and company profile of the key market players. With this large scale Arthritis Marketreport, it can also be estimated how the actions of key players are affecting the sales, import, export, revenue and CAGR values. The report also helps analyze the most appropriate method for the distribution of certain products. This market study also estimates the market status, market share, growth rate, sales volume, future trends, market drivers, market restraints, revenue generation, opportunities and challenges, risks and entry barriers, sales channels, and distributors

Top Key Vendors Covered in the report:

AbbVie Inc.; Pfizer Inc.; Amgen Inc.; Johnson & Johnson Services, Inc.; CELGENE CORPORATION; Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd; UCB S.A.; Gilead Sciences, Inc.; Eli Lilly and Company; Novartis AG; Sanofi; AstraZeneca; Astellas Pharma Inc.; Galapagos NV; Taisho Pharmaceutical Holdings Co., Ltd.; Boehringer Ingelheim GmbH; Swedish Orphan Biovitrum AB (publ); Regeneron Pharmaceuticals; Abiogen Pharma Spa; Merck & Co., Inc.; Kolon TissueGene, Inc.; Ampio Pharmaceuticals Inc.; GlaxoSmithKline plc among others.

Regions included:

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, and Italy)

Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)

South America (Brazil, Argentina, Colombia)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

How Does This Market Insights Help?

Key Pointers Covered in the Arthritis Market Industry Trends and Forecast to 2026

Why choose us:

1. We share precise and exact information about the market forecast;2. Our reports have been examined by professional experts of the industry, which makes them beneficial for the company to maximize their return on investment;3. The analysis acknowledges that the sector players key drivers of both conflicts and Arthritis growth assess the impact of limitations as well as the opportunities on the sector;4. Data regarding Arthritis industry share by every item fragment, alongside their reasonable worth, have been served in the report;5. We provide statistic information, strategic and analysis tool results to provide a sophisticated landscape and target key market players. This will help the company to increase its efficiency;6. Our report helps readers decipher the current and future constraints of the Arthritis market and optimal business strategies to enhance market development;

A complete value chain of the global Arthritis market is presented in the research report. It is associated with the review of the downstream and upstream components of the Arthritis Market. The market is bifurcated on the basis of the categories of products and customer application segments. The market analysis demonstrates the expansion of each segment of the global Arthritis market. The research report assists the user in taking a decisive step that will be a milestone in developing and expanding their businesses in the global Arthritis market.

Get Table Of Contents of This Premium Research For Free: https://www.databridgemarketresearch.com/toc/?dbmr=global-arthritis-market&utm_source=&KA

Major Highlights of TOC covers:

Chapter 1: Methodology & Scope

Chapter 2: Executive Summary

Chapter 3: Arthritis Industry Insights

Chapter 4: Arthritis Market, By Region

Chapter 5: Company Profile

And More..

For More Information or Query or Customization before Buying, Visit at: https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-arthritis-market&utm_source=&KA

Customization of the Report

Data Bridge Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Thanks for reading this article you can also get individual chapter wise section or region wise report versions like North America, Europe, MEA or Asia Pacific.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rates

Contact:

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Corporatesales@databridgemarketresearch.com

See the original post:
Arthritis Market Expected to Witness High Growth over the Forecast Period 2019 2026 - Kewaskum Statesman News Journal

Read More...

Rheumatology Leaders and Patient Advocates Urge Congress to Address Care Challenges Exacerbated by COVID-19 During the Virtual Advocates for Arthritis…

Tuesday, September 15th, 2020

ATLANTA, Sept. 14, 2020 (GLOBE NEWSWIRE) -- ATLANTA The American College of Rheumatology (ACR) will hold its first virtual Advocates for Arthritis event on Tuesday, Sept. 15, where more than 120 rheumatologists, rheumatology health professionals, and patient advocates will meet with lawmakers via video to discuss the healthcare challenges they are facing in the midst of COVID-19. During the event, advocates will urge lawmakers to adopt legislation that ensures continued delivery of accessible, safe and affordable care throughout this public health emergency and beyond.

The pandemic has altered almost every aspect of our rheumatology practices, said ACR President Ellen Gravallese, MD. It has impacted our patients lives significantly and required us to create new ways of delivering care through improved telehealth and other adaptations.

Rheumatology providers face significant resource challenges as a result of the current climate. As providers work to balance patient safety and continued access to care, many have been forced to retool their operations, move a significant portion of visits to telehealth, source their own personal protective equipment (PPE), and help patients navigate drug supply challenges while in many cases operating with less staff due to social distancing protocols, furloughs and layoffs.

Meanwhile, patients are concerned about their ability to access rheumatic care while avoiding exposure to the SARS-CoV-2 virus. A recent national patient survey conducted by the ACR found a 52 percent decline since 2019 among patients who say they are currently being treated by a rheumatology provider. Further, 66 percent of respondents reported using telehealth for rheumatology visits, with COVID-19 cited as the most common reason. While telehealth has been a welcome option for providers and patients alike, some visits such as those involving biologic therapy infusions must be conducted in-person via an office visit. Additionally, the rheumatology workforce shortage has made it increasingly difficult for patients in rural areas to find a practicing rheumatologist.

According to the latest federal estimates, 54 million Americans have a doctor-diagnosed rheumatic disease. A recent academic study suggests that number that could be as high as 91 million when taking into account symptoms reported by undiagnosed individuals. Even though as many as one-quarter to one-third of U.S. adults may be living with a rheumatic disease, there is an average of only one practicing rheumatologist for every 40,000 people, while it is estimated that the U.S. will need thousands more adult rheumatologists by 2030 to meet the challenges caused by a rapidly aging population and a fast-retiring workforce.

To address these challenges and ensure the continued delivery of high-quality care, rheumatology providers and patients are encouraging Congressional leaders to adopt the following legislative solutions:

Noting the precarious financial state of cognitive care specialists who treat complex conditions, rheumatology leaders are also urging lawmakers to support the Centers for Medicare & Medicaid Services important updates to the Physician Fee Schedule slated to take effect in January 2021. Established in concert with the American Medical Association, these updated reimbursements for complex office visits also known as Evaluation and Management (E/M) visits are critical to ensuring specialties on the front lines of treating chronic illness can continue serving patients in need.

While the rheumatology community has adapted to meet these challenges head-on, there is serious concern about the long-term sustainability of this new practice landscape without additional, targeted federal interventions and funding support from lawmakers, said Gravallese.

# # #

The American College of Rheumatology (ACR) is an international medical society representing over 7,700 rheumatologists and rheumatology health professionals with a mission to empower rheumatology professionals to excel in their specialty. In doing so, the ACR offers education, research, advocacy and practice management support to help its members continue their innovative work and provide quality patient care. Rheumatologists are experts in the diagnosis, management and treatment of more than 100 different types of arthritis and rheumatic diseases. For more information, visit http://www.rheumatology.org.

Go here to read the rest:
Rheumatology Leaders and Patient Advocates Urge Congress to Address Care Challenges Exacerbated by COVID-19 During the Virtual Advocates for Arthritis...

Read More...

Artificial Cartilage Implant Market: Durable cartilage implantation are expected to gain a prominent status in the near future – BioSpace

Tuesday, September 15th, 2020

Global Artificial Cartilage Implant Market: An Overview

Cartilage is a semi-solid dedicated connective tissue. It performs a wide range of roles in the human body. It is designed to bear weight, give support, torsion, and bending, and resists tension. Autologous chondrocyte implantation (ACI) is an advanced cartilage implantation method used in the new formation of the impaired articular cartilage.

Read Report Overview - https://www.transparencymarketresearch.com/artificial-cartilage-implant-market.html

According to the National Joint Registry in the U.K., approximately 160,000 people undergo knee replacement procedures each year. The growing research and developments in relation to synthetic materials, repair procedures, and technologies like 3-D printing are expected to bring major changes to artificial cartilage implant medical procedures in the near future.

The Food and Drug Administration in the U.S. recently granted an approval for synthetic cartilage implants for arthritis. Arthritis is a common ailment among old people. Additionally, the global artificial cartilage implant market is expected to offer treatment for important body parts such as the toe, which bears a major brunt while walking and lifting the body.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=61764

The Transparency Market Research (TMR) report provides an astute analysis of the global artificial cartilage implant market, which includes an in-depth analysis of development indicators and demand parameters that could influence the growth of this market. Main market parameters such as demand drivers and challenges of the global artificial cartilage implant market are discussed at length in this report.

Global Artificial Cartilage Implant Market: Key Trends

Currently, there are over 54.4 million adults in the U.S. who suffer from gout, rheumatoid arthritis, and common arthritis, according to Centers for Disease Control and Prevention. The number is expected to increase rapidly due to growing cases of geriatric ailments. Additionally, ailments like diabetes and lifestyle-related issues such as lack of exercise and fast foods are expected to result in more growth for the artificial cartilage implant market.

Request for Analysis of COVID-19 Impact on Artificial Cartilage Implant Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=61764

Current cartilage implants in the market are not permanent solutions. Additionally, people who undergo surgeries experience immense pain when the connective tissue needs to be replaced. Hence, innovative technologies like durable cartilage implantation are expected to gain a prominent status in the near future. These technologies still in the pipeline of government body approvals replicate both flexibility and strength of the original tissue, and is expected to drive the global artificial cartilage implant market.

The global artificial cartilage implant market also faces some challenges in the near future. The key challenge in the artificial cartilage implant is the high cost of the replacement surgeries. Also stringent regulation procedures by the FDA are also expected hinder the market growth. However, newer synthetic materials which cause fewer complications during surgeries and increase the lifeline of the tissue are expected to drive growth.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=61764

Global Artificial Cartilage Implant Market: Regional Outlook

Region wise, the upcoming report by TMR can offer insights into the global artificial cartilage implant market in North America, Western Europe, Asia-Pacific, Eastern Europe, Latin America, Middle East and Africa.

The artificial cartilage implant market in North America is expected to bag a notable share of the global artificial cartilage implant market. Large number of knee replacements, increasing geriatric population, and favorable healthcare insurance policies in the U.S. are the driving factors for the markets growth in North America. The artificial cartilage implant market in Asia Pacific is expected to register robust growth. The Asia Pacific market is expected to register significant CAGR growth during the forecast period. Large population, growing number of elderly people, and increasing public and private funding for research and modernization of medical care infrastructure will contribute to the growth of artificial cartilage market in Asia Pacific region.

Pre Book Artificial Cartilage Implant Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=61764&ltype=S

Global Artificial Cartilage Implant Market: Competitive Dynamics

A few of the main players in global artificial cartilage implant market are Azellon Cell Therapeutics, Biomet, Inc., DePuy, Anika Therapeutics, and CellGenix.

Browse more Trending Report Transparency Market Research:

Ophthalmic Equipment Market: https://www.transparencymarketresearch.com/ophthalmic-equipment-market.html

Tissue Heart Valves Market: https://www.transparencymarketresearch.com/tissue-heart-valves-market.html

Microarray Scanner Market: https://www.transparencymarketresearch.com/microarray-scanner-market.html

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Mr. Rohit BhiseyTransparency Market Research

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

See more here:
Artificial Cartilage Implant Market: Durable cartilage implantation are expected to gain a prominent status in the near future - BioSpace

Read More...

Rheumatoid arthritis awareness week launched in the UK | ITV News – ITV News

Tuesday, September 15th, 2020

Action on rheumatoid arthritis urgent as new data suggest thousands affected constantly experience abuse, stigma and discrimination

A national rheumatoid arthritis (RA) campaign was launched on Monday.We R.A. Prioritygives a voice to the hundreds of thousands of adults of all ages with this often-invisible disease and challenges the potentially damaging misperceptions that persist around the condition.

Findings from new research reinforce the reality of RA in the UK today, with data suggesting many young adults with the condition regularly labelled as having an old persons disease, whilst many continue to face stigma at work and among friends and family.The We R.A. Priority campaign aims to empower those with RA to address perceptions and show how, when RA is treated as a priority, the impact can be life changing, for the individual and for society.

Over 400,000 people across the UK live with RA an incurable, systemic auto-immune condition that can cause intense pain and fatigue to those affected and, if not treated appropriately, can cause irreversible damage to joints and disability.The campaign is calling for urgent change to put a stop to the misperceptions of RA and continued social and economic impact, specifically:

RA needs a unique identity:

differentiated from other arthritic conditions which are not caused by auto-immune dysfunction

Recognition that many symptoms of RA are invisible and debilitating:

so that key audiences such as healthcare professionals, government, employers, venues, transport providers, shops, can take simple steps to better support those affected

Clare Jacklin, Chief Executiveat the National Rheumatoid Arthritis Society (NRAS) said: Over 400,000 people across the UK live with rheumatoid arthritis (RA); yet, in 2020, misunderstanding around the condition is still alarmingly high and is causing deep distress for individuals as well as a major fiscal and social cost to society.

"These are people with incredible potential and to still be in the situation where people are shouted at in the street for using disabled parking spaces because they dont look like they should or they lose their job or overlooked for career progression because of their RA, is simply unacceptable.

"Today the community is calling for urgent action. By taking just simple steps to change attitudes, we can change thousands of lives. Without this, the community could face more challenges as COVID-19 recovery plans establishes other, more recognised conditions as more important. We must act now. The reality is that those affected by RA are capable, and often inspirational people with so much to offer, as long as RA is a priority.

Data collected as part of the campaign captures feedback from over 280 people living with RA insights include:

"These are people with incredible potential and to still be in the situation where people are shouted at in the street for using disabled parking spaces because they dont look like they should or they lose their job or overlooked for career progression because of their RA, is simply unacceptable.

"Today the community is calling for urgent action. By taking just simple steps to change attitudes, we can change thousands of lives. Without this, the community could face more challenges as COVID-19 recovery plans establishes other, more recognised conditions as more important. We must act now. The reality is that those affected by RA are capable, and often inspirational people with so much to offer, as long as RA is a priority.

Data collected as part of the campaign captures feedback from over 280 people living with RA insights include:

93% of people noted that the general public fail to differentiate RA from other forms of arthritis, labelling it an older persons disease - this is despite more than half of all respondents (52%) being diagnosed under the age of 45

85% of people have experienced direct stigma as a result of RA being invisible ranging from accusations of cheating the state benefit system to being called lazy

69% of people have experienced negative attitudes when using disabled facilities as a result of their invisible symptoms with some even receiving verbal abuse

Almost half of people (47%) admitted to not feeling confident to talk to their close friends and family about their condition

One in ten people have lost a job or promotion as a result of their disease:

Previous research has shown that 60% of people with RA stop working more than 5 years earlier than they would have expected to if they had not been diagnosed with RA

More than half of respondents have lied or actively hidden their condition from friends and family, while 80% have pretended to be well enough to socialise in fear of damaging relationships or losing friendships.

Continued here:
Rheumatoid arthritis awareness week launched in the UK | ITV News - ITV News

Read More...

Switching Antirheumatic Therapies Has Low Risk of Clinical Worsening – MD Magazine

Tuesday, September 15th, 2020

There is a very low risk of rheumatoid arthritis worsening as a result of changing treatments due to partial or inadequate response, a new study finds. In fact, more than half of such patients treated with adalimumab who had switched to sarilumab experienced clinically meaningful improvements.

These findings were presented at the Clinical Congress of Rheumatology (CCR) East 2020 meeting.

Current guidelines recommend making any necessary therapeutic adjustments if rheumatoid arthritis patients fail to meet treatment goals or remission. Although patients may express health concerns over switching, there have been no data that assesses the association between therapy switching and disease exacerbation.

To fill this gap, a team led by Jeffrey Curtis, MD, MS, MPH, Professor of Medicine at the University of Alabama at Birmingham, performed a post-hoc analysis of the MONARCH Open-Label Extension (OLE) study and evaluated the effects of switching from adalimumab to sarilumab in patients who had partial response to treatment.

Patients who had been randomized to receive 40 mg of adalimumab during the double-blind phase were then transferred to receive 200 mg of sarilumab at the start of the extension study. Those initially receiving sarilumab continued with the regiment during open-label.

The extension study had enrolled a total 320 patients, and 155 ended up switching to the sarilumab group, with 165 maintaining sarilumab treatment.

At OLE baseline, 52% of the population had experienced partial response during the double-blind phase. The investigators noted that, as expected, partial responders were more prominent in the switch group (59%)versus the continuation group (45%).

Furthermore, the continuation group partial responders had similar but numerically lower disease activity scores at OLE baselinewith the exception of tender joint count (TJC) and swollen joint count (SJC).

For the post-hoc analysis, Curtis and team defined partial response as patients with continued moderate-to-high disease activity (Clinical Disease Activity Index [CDAI] > 10) at OLE baseline, regardless of if minimal clinically important difference (MCID) and CDAI had improved following the double-blind phase.

The MCID threshold for patients with high-disease activity at double-blind phase baseline (CDAI<22) was 12 units. The threshold for those with moderate disease activity was 6 units.

After week 24, they noted that only a few partial responders in the switch (6%) and continuation (4%) experienced a worsening of disease activity.

On the contrary, up to 57% of patients in the switch group and 43% in the continuation group experienced improvements in disease activity.

There was no observed change of disease activity in 37% and 53% of the switch and continuation cohorts, respectively.

And finally, the team reported that between OLE baseline and week 24, the mean changes in efficacy parameters and patient reported outcomes had numerically increased. The only exception was SJC28.

A small risk of worsening with the substantial likelihood of meaningful improvement may help alleviate patient fears of worsening when considering a switch to an alternative therapy, such as sarilumab, they concluded.

The study, Low Probability of Clinical Worsening Following Switching Biologic Disease-Modifying Antirheumatic Drug in Patients with Rheumatoid Arthritis and Partial Response to Adalimumab, was presented at CCR East.

Read more:
Switching Antirheumatic Therapies Has Low Risk of Clinical Worsening - MD Magazine

Read More...

Value of Psoriatic Arthritis Therapeutics Market Predicted to Surpass US$ by the of 2017 2025 – The Daily Chronicle

Tuesday, September 15th, 2020

The continuing spread of Coronavirus (COVID-19) amongst major global economies has become an important factor of concern for import and export activities. Learn how companies in the Psoriatic Arthritis Therapeutics market are responding to the Coronavirus crisis by gaining efficacy in alternative strategies that are stabilizing various business activities. Browse through our latest research analysis on COVID-19 and its impact over the global market landscape.

Why Choose Persistence Market Research?

Request Sample Report @ https://www.persistencemarketresearch.co/samples/13729

The report on the global Psoriatic Arthritis Therapeutics market published by Persistence Market Research (PMR) provides a clear understanding of the flight of the Psoriatic Arthritis Therapeutics market over the forecast period (20XX-20XX). The study introspects the various factors that are tipped to influence the growth of the Psoriatic Arthritis Therapeutics market in the upcoming years. The current trends, growth opportunities, restraints, and major challenges faced by market players in the Psoriatic Arthritis Therapeutics market are analyzed in the report.

The study reveals that the global Psoriatic Arthritis Therapeutics market is projected to reach a market value of ~US$XX by the end of 20XX and grow at a CAGR of ~XX% during the assessment period. Further, a qualitative and quantitative analysis of the Psoriatic Arthritis Therapeutics market based on data collected from various credible sources in the market value chain is included in the report along with relevant tables, graphs, and figures.

Relevant Takeaways from Report:

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/13729

Psoriatic Arthritis Therapeutics Market Segmentation

By Region

The presented study throws light on the current and future prospects of the Psoriatic Arthritis Therapeutics market in various geographies such as:

By Product Type

The report highlights the product adoption pattern of various products in the Psoriatic Arthritis Therapeutics market and provides intricate insights such as the consumption volume,

By End-User

key players and product offerings

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/13729

The report addresses the following doubts related to the Psoriatic Arthritis Therapeutics market:

The rest is here:
Value of Psoriatic Arthritis Therapeutics Market Predicted to Surpass US$ by the of 2017 2025 - The Daily Chronicle

Read More...

Canine Arthritis Treatment Market : Facts, Figures and Analytical Insights, 2019 to 2025 – The Daily Chronicle

Tuesday, September 15th, 2020

Global Canine Arthritis Treatment Market research report presents a comprehensive overview of market size, share, evolution, trends, and forecast, and growth opportunities of Canine Arthritis Treatment market by product type, application, key manufacturers and key regions and countries. This report offers comprehensive analysis on global Canine Arthritis Treatment market along with, market trends, drivers, and restraints of the Canine Arthritis Treatment market. In-depth study of market size with data Tables, Bar & Pie Charts, and Graphs & Statistics which helps easy to understand detailed breakdown of market.

Note: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.researchmoz.com/enquiry.php?type=S&repid=2685433&source=atm

the following market information:Global Canine Arthritis Treatment Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)Global Canine Arthritis Treatment Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)Global Canine Arthritis Treatment Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)Global Canine Arthritis Treatment Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)

Key market playersMajor competitors identified in this market include Elanco (Eli Lilly and Company), Boehringer Ingelheim, Zoetis Inc, Vetoquinol S.A., Bayer AG, Aratana Therapeutics Inc, Norbrook Laboratories Limited, VetStem Biopharma, Dechra Pharmaceuticals Plc, etc.

Based on the Region:Asia-Pacific (China, Japan, South Korea, India and ASEAN)North America (US and Canada)Europe (Germany, France, UK and Italy)Rest of World (Latin America, Middle East & Africa)

Based on the Type:Non-Steroidal Anti-Inflammatory DrugsOpioids

Based on the Application:Veterinary Hospitals and ClinicsDrug StoresE-commerce

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2685433&source=atm

This detailed report on Canine Arthritis Treatment market largely focuses on prominent facets such as product portfolio, payment channels, service offerings, applications, in addition to technological sophistication. The report lends versatile cues on market size and growth traits, besides also offering an in-depth section on opportunity mapping as well as barrier analysis, thus encouraging report readers to incur growth in global Canine Arthritis Treatment market.

This comprehensive research- documentary on global Canine Arthritis Treatment market is a holistic perspective of market developments, factors, dynamics, trends and challenges that decide growth trajectory of global Canine Arthritis Treatment market.

Apart from highlighting these vital realms, the report also includes critical understanding on notable developments and growth estimation across regions at a global context in this report on Canine Arthritis Treatment market.

These leading players are analyzed at length, complete with their product portfolio and company profiles to decipher crucial market findings. Additionally, the competitive landscape of the Canine Arthritis Treatment market is also evaluated at length in the report, to identify and analyze leading service providers.

Geographically, the detailed analysis of consumption, revenue, Canine Arthritis Treatment market share and growth rate, historic and forecast (2015-2026) of the following regions are covered-

North America (USA, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Columbia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

All the notable Canine Arthritis Treatment market specific dimensions are studied and analyzed at length in the report to arrive at conclusive insights. Further, a dedicated section on regional overview of the Canine Arthritis Treatment market is also included in the report to identify lucrative growth hubs.

This Canine Arthritis Treatment market also harps on competition intensity, thoroughly identifying and evaluating leading players in the Canine Arthritis Treatment market and their growth stimulators. Besides these aforementioned factors and attributes of the Canine Arthritis Treatment market, this report specifically decodes notable findings and concludes on innumerable factors and growth stimulating decisions that make this Canine Arthritis Treatment market a highly profitable.

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2685433&licType=S&source=atm

A thorough take on essential elements such as drivers, threats, challenges, opportunities are thoroughly assessed and analyzed to arrive at logical conclusions. As the report proceeds further, Even further in the report emphasis has been lent on current, historical, as well as future growth tendencies to make accurate growth estimations based on market size, value, volume, demand and supply trends as well as growth rate.

Other vital factors related to the Canine Arthritis Treatment market such as scope, growth potential, profitability, and structural break-down have been innately roped in this Canine Arthritis Treatment report to accelerate market growth. This research compilation on Canine Arthritis Treatment market is a meticulous compilation of in-depth primary and secondary research. The report also lists ample understanding on various analytical practices such as SWOT and PESTEL analysis to guide optimum profits in Canine Arthritis Treatment market. The report is a conscious attempt to unearth market specific developments to ignite growth specific market discretion.

For More Information Kindly Contact:

ResearchMoz

Mr. Rohit Bhisey,

90 State Street,

Albany NY,

United States 12207

Tel: +1-518-621-2074

USA-Canada Toll Free: 866-997-4948

Email: [emailprotected]

Follow this link:
Canine Arthritis Treatment Market : Facts, Figures and Analytical Insights, 2019 to 2025 - The Daily Chronicle

Read More...

Insights into the Rheumatoid Arthritis Industry to 2030 – Develop Business Strategies by Understanding Trends – ResearchAndMarkets.com – Business Wire

Monday, August 31st, 2020

DUBLIN--(BUSINESS WIRE)--The "Rheumatoid Arthritis (RA) - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the disease, historical and forecasted RA epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Rheumatoid Arthritis (RA) Understanding

Rheumatoid Arthritis Overview

Rheumatoid arthritis (RA) is an autoimmune or chronic inflammatory disease that is known to impact the joints of the body adversely. An autoimmune disorder is a condition where the immune system starts making antinuclear bodies instead of antibodies which directs them to cause self-injury to the body, on the onset of disease, the immune response primarily attacks and harm the joints. RA is more common in women and about 75% of RA patients are women. Around 1 to 3% of women may get rheumatoid arthritis in their lifetime. The disease most often begins between the ages of 30 and 50. However, RA can start at any age.

Clinically, the symptoms of RA significantly differ between early-stage RA and insufficiently treated later stages of the disease. Early-stage RA is characterized by generalized disease symptoms such as fatigue, flu-like feeling, swollen and tender joints, and morning stiffness; and is paralleled by elevated levels of C-reactive protein (CRP) and an increased erythrocyte sedimentation rate (ESR). In contrast, insufficiently treated RA displays a complex clinical picture with the occurrence of serious systemic manifestations such as pleural effusions, lung nodules and interstitial lung disease, lymphomas, vasculitis in small or medium-sized arteries, keratoconjunctivitis, atherosclerosis, hematologic abnormalities (e.g., anemia, leukopenia, neutropenia, eosinophilia, thrombocytopenia, or thrombocytosis), joint misalignments, loss of range of motion, bone erosion, cartilage destruction, and rheumatic nodules. These systemic manifestations caused by the chronic inflammatory state in RA patients result in increased mortality.

Rheumatoid Arthritis Diagnosis

Typically, RA is diagnosed by a combination of patient's symptoms, results of doctors examination, assessment of risk factors, family history, a joint assessment by ultrasound sonography, and assessment of laboratory markers such as elevated levels of CRP and ESR in serum and detection of RA-specific autoantibodies.

More than two thirds of RA patients have reported moderate to severe symptoms and having disease activity (DAS) score of 3.2 or above. And by this stage, most of the patients have joints that are experiencing swelling and pain and may have deformities, like malalignment, in some joints as a result of cartilage destruction.

Epidemiology Perspective

The RA epidemiology division provides the insights about historical and current RA patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

In the year 2017, the total prevalent cases of RA was 4,356,793 cases in the 7MM which are expected to grow during the study period, i.e., 2017-2030.

The disease epidemiology covered in the report provides historical as well as forecasted RA epidemiology segmented as [Total Prevalent Cases of RA, Diagnosed cases of RA, Gender-specific cases of RA, Diagnosed cases of RA by Age Distribution, Severity-specific cases of RA, Patients on targeted therapies of RA, and Line-Wise Treated Cases of RA] scenario of RA in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- RA Epidemiology

Estimates show that the highest cases of RA in the 7MM were in the United States, followed by Japan, Germany, the United Kingdom, France, Italy, and Spain in 2017.

Reasons to buy

Key Assessments

Geographies Covered

Study Period: 2017-2030

For more information about this report visit https://www.researchandmarkets.com/r/fxpicl

Read the original:
Insights into the Rheumatoid Arthritis Industry to 2030 - Develop Business Strategies by Understanding Trends - ResearchAndMarkets.com - Business Wire

Read More...

Most Adults with Lupus or Common Types of Arthritis Have Similar Risks of Getting Admitted to Hospital as Other Patients with COVID-19 – NYU Langone…

Monday, August 31st, 2020

Most adults with systemic lupus erythematosus (SLE) are not at increased risk of hospitalization from 2019 coronavirus disease (COVID-19) due to medications used to dampen their altered immune system, the cause of the disease. Nor are most people with more common types of arthritis, such as rheumatoid, psoriatic, and spondyloarthritis, at greater risk of hospitalization from COVID-19, a pair of new reports shows.

SLE, known widely as lupus, along with common forms of arthritis are autoimmune conditions caused by the immune systems mistaken attack on a persons own tissues, leading to inflammation in the joints, skin, kidneys, and other parts of the body. The majority of those affected by these diseases are women.

Although the new studies, led by NYU Grossman School of Medicine researchers, show that for some of those affected the use of steroid medications to reduce inflammation slightly increased the likelihood of needing hospital care, researchers say the results should be reassuring to patients overall.

Many people are taking steroids or other immunosuppressing medications, especially newer biologic drugs, to prevent their immune systems attack on their tissues. And the researchers say their patients report feeling added anxiety that their treatments make them more susceptible to the dangers of coronavirus infection.

In the first study, published recently in the journal Arthritis and Rheumatology, researchers closely monitored the health of 226 adult patients, mostly Black, Hispanic, and female, receiving treatment at NYU Langone Health clinics or NYC Health + Hospitals/Bellevue for mild to severe forms of lupus. All were surveyed by phone or email, or had their medical records checked between April 13 and June 1, when the pandemic peaked in the New York City region. Twenty-four were hospitalized out of 41 who were formally diagnosed with COVID-19, and 4 of them died. Another 42 had COVID-19like symptoms but were not formally tested.

For the second study, also published in Arthritis and Rheumatology, researchers monitored 103 mostly white women being treated at NYU Langone Health clinics between March 3 and May 4 for inflammatory arthritis, which unlike common osteoarthritis, does not primarily result from joint wear and tear. All tested positive for COVID-19 or had symptoms highly suggesting they were infected. Twenty-seven (26 percent) were hospitalized, with 4 deaths (4 percent).

Researchers say their latest study findings showed that patients with lupus taking immune-suppressing medications, such as mycophenolate mofetil (CellCept) and azathioprine (Imuran), had no greater risk of hospitalization (15 out of 24) than patients with lupus not using the medications (9 of 17). Similarly, hospitalization rates for people with inflammatory arthritis (26 percent) and COVID-19 were also no greater than seen for all New Yorkers (25 percent, according to city figures).

Among the research teams other findings was that patients taking biologic drugs for arthritis, such as adalimumab (Humira) and etanercept (Enbrel), which are made from living cells, or the antiviral hydroxychloroquine, were at no greater or lesser risk of hospitalization than those not taking the drugs. However, those taking glucocorticoids, a type of steroid, even in mild doses, were upwards of 10 times more likely to be hospitalized than patients with arthritis not using steroids. The researchers caution that although statistically significant, the studys small size may overestimate the actual risk.

Our findings represent the largest of its kind for American patients with lupus or arthritis and COVID-19, and should reassure most patients, especially those on immunosuppressant therapy, that they are at no greater risk of having to be admitted to hospital from COVID-19 than other lupus or arthritis patients, says one of the studies co-lead investigators, Ruth Fernandez-Ruiz, MD.

People with lupus or inflammatory arthritis have the same risk factors for getting seriously ill from COVID-19 as people without these disorders, says Dr. Fernandez-Ruiz, a postdoctoral fellow in rheumatology in the Department of Medicine at NYU Langone.

These shared risk factors, she says, which overall more than double peoples risk of hospitalization from COVID-19, are having multiple underlying health conditions, such as obesity, hypertension, and diabetes.

Patients receiving therapy for lupus and inflammatory arthritis should not automatically stop taking their medications for fear that they would be worse off if they also caught the coronavirus, says another of the studies co-lead investigators, Rebecca Haberman, MD. Instead, rheumatology patients should consult with their medical provider about their overall risk factors for COVID-19 and make plans accordingly, says Dr. Haberman, a clinical instructor in rheumatology in the Department of Medicine at NYU Langone.

Dr. Fernandez-Ruiz says the team now plans to test patients with lupus and patients with arthritis for coronavirus antibodies to see how many study participants were infected at some point and whether any were at greater or lesser risk of infection.

Funding support for the studies was provided by National Institutes of Health grants P50 AR07059, R01 AR074500, and T32 AR069515. Additional support was provided by Bloomberg Philanthropies COVID-19 Response Initiative Grants, The Riley Family Foundation, The Snyder Family Foundation, and Pfizers COVID-19 Competitive Grants Program.

Dr. Haberman and other study investigators have participated in other research projects sponsored by various manufacturers of arthritis drugs, as well as served on advisory boards to AbbVie, Amgen, Astrazeneca, Bristol-Myers Squibb, Celgene, Corrona, Eli Lilly, GlaxoSmithKline, Janssen, Johnson & Johnson, Novartis, Pfizer, Sanofi, and UCB. All of these arrangements are being managed in accordance with the policies and practices of NYU Langone.

Besides Dr. Haberman and Dr. Fernandez-Ruiz, other NYU Langone researchers involved in the studies are co-lead investigators Mala Masson, Rochelle L. Castillo, MD, and Alan Chen; senior investigators Amit Saxena, MD, Peter M. Izmirly, MD, Samrachana Adhikari, PhD, and Jose U. Scher, MD; and co-investigators Allison Guttman, Philip Carlucci, Kristina Deonaraine, Michael Golpanian, Kimberly Robins, Miao Chang, H. Michael Belmont, MD, Jill P. Buyon, MD, Ashira Blazer, MD, Di Yan, and Deborah Ramirez. Additional study co-investigators are Mimi Kim at Albert Einstein College of Medicine in New York; and Benjamin Myers at Cornell University in Ithaca, New York.

David MarchPhone: 212-404-3528david.march@nyulangone.org

Read the rest here:
Most Adults with Lupus or Common Types of Arthritis Have Similar Risks of Getting Admitted to Hospital as Other Patients with COVID-19 - NYU Langone...

Read More...

Understanding the Risk of Joint Replacement in Patients With Rheumatoid Arthritis – AJMC.com Managed Markets Network

Monday, August 31st, 2020

Disease-modifying antirheumatic drugs have reduced the need for total knee and hip arthroplasties (TKA and THA) in patients with rheumatoid arthritis (RA). However, there is still a far greater long-term risk of undergoing THA or TKA in patients with RA compared with patients who do not have RA, according to a study published in The Journal of Arthroplasty.

Since 1991 the proportion of patients with RA who are required to undergo TKA has dropped from 21.0% to as low as 2.4%. However, the few previous studies have been based on populations in the United States and Europe.

Patients with RA who experience joint destruction, intractable joint pain, or unacceptable functional decline usually require joint arthroplasty, the authors explained.

Researchers conducted a large-scale retrospective cohort study of 32,949 patients in Taiwan who were diagnosed with RA from 2000 to 2012. They were matched with 32,949 non-RA controls. Patients with RA had a more unfavorable Charlson comorbidity index score.

After adjusting for demographics and comorbidities, patients in the RA cohort had a 4.02-fold higher risk of undergoing TKA or THA (95% CI, 3.67-4.41). Factors that significantly increased the risk of THA or TKA were increasing age, living in an area of low urbanization, working as a manual laborer, 1 point in CCI score, having hypertension, or having gout.

Using multivariable stratified analyses, the researchers found that patients younger than 40 years actually had the highest risk of THA or TKA (adjusted hazard ratio, 43.18; 95% CI, 16.01-116.47). Careful interpretation of the results is needed because of relatively small sample size of this age interval, the authors noted.

However, they did note a previous study had shown young-onset RA was correlated with reduced radiographic progression and better functional score after 3 years. Those findings taken with the findings from the current study suggest that despite the better short-term outcome, patients with young-onset RA are still more at risk of undergoing TKA and THA compared with patients with late-onset RA, the authors wrote.

Based on the actual surgical procedures performed, patients with RA had a 4.56-fold higher risk of requiring THA, a 3.85-fold higher risk of TKA, and a 19.39-fold higher risk of requiring both THA and TKA compared with the non-RA cohort.

We recommend that future researchers can include more detailed documented dose or regimen of DMARDs utilization to verify the doseresponse effect in reducing the THA or TKA in RA patients, the authors concluded.

Reference

Lee Y-H, Ko P-Y, Kao S-L, Lin M-C, Cheng-Chung Wei J. Risk of total knee and hip arthroplasty in patients with rheumatoid arthritis: a 12-year retrospective cohort study of 65,898 patients. J Arthroplasty. Published online July 2, 2020. doi:10.1016/j.arth.2020.06.085

Go here to read the rest:
Understanding the Risk of Joint Replacement in Patients With Rheumatoid Arthritis - AJMC.com Managed Markets Network

Read More...

Joint Pain Injections Market: Investments by key players is driving the global market – BioSpace

Monday, August 31st, 2020

Transparency Market Research (TMR) has published a new report titled, Joint Pain Injections Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 20182026. According to the report, theglobal joint pain injections marketis expected to exceed a value of US$ 3 Bn by the end of 2018. The global market is anticipated to surpass US$ 6 Bn by 2026 and expand at a high single digit CAGR from 2018 to 2026. Rise in number of geriatric patients, increase in awareness regarding joint disorders, and high unmet medical needs are expected to augment the global market from 2018 to 2026. The joint pain injections market is projected to expand, owing to an increase in the prevalence of joint pain among the population, demand for better treatments, and development of healthcare infrastructure in various countries across the globe.

Increasing prevalence of arthritis and other bone-related disorders

According to facts published by Arthritis Foundation, arthritis is the leading cause of disability among adults in the U.S. Approximately 54 million adults and 300,000 babies and children in the U.S. suffer from arthritis or any rheumatic condition. More than 78 million people in the U.S. are likely to suffer from doctor-diagnosed arthritis by 2040. Furthermore, osteoarthritis is the most common type of arthritis and affects approximately 31 million people in the U.S. Increasing prevalence of arthritis further boosts the demand for disease modifying treatments, which in turn is anticipated to propel the joint pain injections market during forecast period.

Request Brochure of Report -https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=47664

Increase in prevalence of obesity leading to joint pain

Obesity is considered a risk factor for various joint disorders, especially related to knee, such as knee pain and knee osteoarthritis. According to the fact sheet published by World Health Organization (WHO), worldwide obesity has tripled since 1975. In 2016. 1.9 billion People were overweight and among them, more than 650 million adults were obese. Moreover, approximately 41 million children under the age of 5 were obese in 2016. According to the 2015-2016 National Health and Nutrition Examination Survey (NHANES), more than one in four children of Hispanic origin ages 2 to 19 had obesity, and approximately 47% of adults suffered from obesity. Increasing patient pool in developing countries as well as developed countries is estimated to propel healthcare spending for joint pain treatments in these countries and consequently, drive the joint pain injections market.

Request for Analysis of COVID-19 Impact on Joint Pain Injections Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=47664

High unmet needs in patients with joint pain

Arthritis is the most common cause of joint pain and a major cause of disability and impaired mobility among the population. Currently available treatment options are insufficient, as they primarily focus on symptom relief and pain mitigation. There are no drugs available that can cure, reverse, or halt disease progression such as osteoarthritis. Moreover, some patients are unable to find relief with available treatments and continue to suffer in pain; therefore, there are large unmet needs in patients with joint pain. This provides opportunity for advance treatment options in the joint pain injections market.

Hyaluronic acid injections segment dominates the global market due to increasing acceptance for the treatment of osteoarthritis

In terms of injection type, hyaluronic acid injections is a highly attractive segment of the global joint pain injections market, followed by corticosteroid injections and others segments. This is attributable to the effectiveness of hyaluronic acid injections in the treatment of knee osteoarthritis, where other treatments are contraindicated.According to rapid response report published by CADTH, viscosupplementation with hyaluronic acid in adults with knee osteoarthritis is superior to intra-articular placebo and other conventional medications, such as non-steroidal anti-inflammatory drugs (NSAIDs), in terms of improving knee pain and function with minimum adverse effects.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=47664

North America dominates the global market owing to high acceptance of viscosupplementation in the region

North America dominates the global joint pain injections market due to a large patient pool, increase in the geriatric population, increased obesity, and high acceptance of advanced treatments for the joint pain relief in the region. The region is estimated to maintain its dominance during the forecast period. Viscosupplementation with hyaluronic acid products is approved by US FDA for the treatment of knee osteoarthritis. Moreover, rising healthcare expenditure and increasing investments are key factors that are anticipated to boost the joint pain injections market in the next few years. The joint pain injections market in Asia Pacific is projected to expand at a notable CAGR due to increasing about join disorders in developing countries and rising research initiatives and manufacturing of hyaluronic acid products in Japan.

Buy Joint Pain Injections Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=47664&ltype=S

Investments by key players is driving the globaljoint pain injections market

Major players operating in the joint pain injections market include Allergan Plc., Pfizer Inc., Sanofi, Anika Therapeutics, Inc., Ferring B.V., Bioventus, Flexion Therapeutics, Inc., Zimmer Biomet Holdings, Inc., SEIKAGAKU CORPORATION, and Chugai Pharmaceutical Co., Ltd.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Mr. Rohit BhiseyTransparency Market Research

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

View original post here:
Joint Pain Injections Market: Investments by key players is driving the global market - BioSpace

Read More...

Arthritis pain – the 90p ‘superhero’ vegetable you should add to your diet for joint pain – Express

Monday, August 31st, 2020

Arthritis pain can lead to a number of debilitating symptoms that patients will want to try and avoid.

The condition can make life more difficult when carrying out simply, everyday tasks.

It's crucial that if you develop signs of arthritis, you speak to a doctor as soon as possible to try and find a treatment to relieve your pain.

One of the best ways to avoid arthritis pain is to eat more onions, it's been claimed.

READ MORE: Arthritis pain - the best vegetable to lower your risk of joint pain

"While the cure for arthritis eludes medical science, there are many potent treatments for the condition," it said.

"Chief among these are avoiding foods that exacerbate joint pain and eating foods that reduce it.

"Loaded with immune-boosting properties, garlic and onions are the superhero duo of the produce section.

"Studies have shown that those who eat foods in the allium family, such as garlic and onions, exhibit fewer signs of osteoarthritis and joint pain."

Common arthritis symptoms include joint pain, inflammation, and restricted movement.

There are two key types of arthritis in the UK; osteoarthritis and rheumatoid arthritis.

Osteoarthritis is the most common type of arthritis to be diagnosed in the UK - around nine million people are believed to have osteoarthritis.

Rheumatoid arthritis, meanwhile, is an auto-immune disease that has been diagnosed in about 400,000 individuals.

Follow this link:
Arthritis pain - the 90p 'superhero' vegetable you should add to your diet for joint pain - Express

Read More...

Your Health: How to protect your joints from arthritis – YourErie

Monday, August 31st, 2020

About one in three people between ages 18 and 64 have some type of arthritis.

This common joint disease can wreak havoc on everyday life, but there are some ways to protect yourself.

Its coverage affecting your health.

Running, jumping and climbing stairs or mountains, your joints take a lot of abuse over time. It can lead to osteoarthritis and its not just a disease for the old.

Were seeing arthritis at an earlier age, not only in the knees, but shoulders, really everywhere. Its becoming an epidemic of sorts, said Dr. Matthew Pombo, MD, Emory Orthopedics and Spine Center.

So you can safe guard your joints?

First ditch the high heels as they put pressure on your knees and feet. A three inch heel stresses your foot seven times more than a one inch heel.

You might also want to scrap the sodas. A Harvard study found that men with osteoarthritis who drank more sugary carbonated drinks reported worse symptoms.

You might also want to get active, but ramp it up slowly and be careful of injuries.

We also have a lot of younger people participating in sports and we know that prior injury leads to post-traumatic arthritis, said Dr. Pombo.

Low impact activities such as walking, swimming and biking are best and extra weight is one of the biggest culprits for arthritis pain.

Every additional pound you gain puts four times the stress on your knees.

Research shows that losing as few as eleven pounds cuts your risk for osteoarthritis by 50% with ways to protect your joints.

See the original post:
Your Health: How to protect your joints from arthritis - YourErie

Read More...

Postpartum Arthritis: What to do if you are suffering from joint pain after delivery – Pledge Times

Monday, August 31st, 2020

Postpartum Arthritis: What to do if you are suffering from joint pain after delivery Pledge Times

No Result

View All Result

Let us know the causes of arthritis after delivery and what treatment options are available.

Arthritis after pregnancyArthritis can be troublesome at any age and the disease affects more women than men. Complaints of arthritis may increase after pregnancy, and some women continue to have arthritis pain after delivery. Arthritis can occur after delivery in the wrist, hands, ankles and feet.Cause of postpartum arthritisArthritis after delivery is called postpartum arthritis. The following reasons of arthritis of the child can be:Women who have arthritis before pregnancy can be relieved during pregnancy. Most autoimmune diseases such as rheumatoid arthritis or psoriatic arthritis disappear during pregnancy. This is due to antibodies and immune responses. Symptoms of arthritis may return after delivery.The immune system usually becomes strong after pregnancy. Any pre-allergic or autoimmune diseases such as rheumatoid arthritis can cause lupus due to the hyperactivity of the immune system.Age, obesity, jeans, lack of physical activity, smoking, infection and lack of nutrients in the diet can also cause arthritis or joint pain after pregnancy.Treatment of postpartum arthritisTell a doctor if you are complaining of joint pain or arthritis after delivery. Doctors can give treatment to reduce pain, reduce damage to joints. For this, you will have to go to the doctor periodically for a checkup.Apart from this, it is also very important to have a balanced and nutritious diet. Take calories, burn fat. If you have gained weight after delivery, weight loss can also relieve joint pain. When the weight is high, there is pressure on the erect joints especially on the axes and knees. Overweight increases the risk of arthritis.Being physically active can help reduce pain and improve mood. It also protects against long-term conditions like diabetes, high BP.

Conceive with arthritisThe 2011 study included approximately 74,000 pregnant women. All these women were suffering from Rheumatoid Arthritis and were having difficulty convalescing like normal women. About twenty five percent of these women were trying to conceive for about a year before becoming pregnant. Among women who did not suffer from rheumatoid arthritis, this figure was only sixteen percent.It is very important to control arthritis for at least 3 to 6 months before becoming pregnant.

.

Enneagram 7. The multi-tasker. Growing one step closer every day to leaving my legacy.

No Result

View All Result

Excerpt from:
Postpartum Arthritis: What to do if you are suffering from joint pain after delivery - Pledge Times

Read More...

Rheumatoid arthritis treatment: The fast workout that may provide pain relief – Express

Monday, August 31st, 2020

What did Bye set out to achieve?

According to Bye, numerous studies show that high-intensity interval training is much more effective for improving endurance than moderate intensity training.

"This is true regardless if you're sick or healthy, young or old. We wanted to see if patients with arthritis could handle high intensity training and see the same positive effects," said Bye.

After ten weeks of hard training on a spinning bike twice a week, Bye saw no adverse effects on her study's participants, a group of women with arthritis.

"Rather, we saw a tendency for there to be less inflammation, at least as measured by the inflammation marker CRP, and the participants of the study experienced a solid increase in maximum oxygen intake, meaning that they reduced their risk of cardiovascular disease," Bye said.

The participants also saw a small reduction in BMI, body fat percent and waist measurement, as well as an increase in muscle mass as a result of the training period.

The participants warmed up for ten minutes at 70 per cent of their maximum pulse, and then did four repetitions of high intensity (85-95 percent of max pulse) four-minute intervals.

The break between each interval was about three minutes, at 70 percent of max pulse. The total work-out session lasted about 35 minutes.

"The women who participated in the study found this to be a good, effective method of training, and are mostly very motivated to continue because of the progress they've seen," Bye concluded.

The NHS issues important advice when it comes to trying out different forms of exercise.

"If a particular activity causes your joints to become warm and swollen, or it causes severe pain, then stop and rest," says the health body.

If it does not cause problems, then it is usually fine to continue, notes the health site.

It adds: "If a particular activity always causes a flare-up, it's best to avoid it and find an alternative."

Read the original post:
Rheumatoid arthritis treatment: The fast workout that may provide pain relief - Express

Read More...

Global Arthritis Therapeutic Market: Industry Analysis and forecast (2019 to 2026) – Galus Australis

Monday, August 31st, 2020

Global Arthritis Therapeutics Marketwas valued USD XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at CAGR of 4.8 % during forecast period of 2019 to 2026.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/36112

Global Arthritis Therapeutics MarketThe report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.Arthritis is an inflammatory disorder affecting the joints cause redness, stiffness, resulting in pain and swelling in the joints. More than 100 categories of arthritis are affecting the global population. The most common arthritis conditions are psoriatic arthritis, rheumatoid arthritis, and osteoarthritis. The osteoarthritis affects a majority of the geriatric population, in severe joint pain and affecting their movement. Psoriatic Arthritis therapeutics contains drugs that help to reduce pain and inflammation.

Global Arthritis Therapeutic Market Drivers and RestrainsThe significant growth of the global arthritis therapeutics market is credited to investments in research & development, strong product pipeline, increasing patient pool suffering from arthritis. Furthermore, rise in the geriatric population is another factor fueling the growth of the global arthritis therapeutics market. Patients gone under treatment with Disease-Modifying Antirheumatic Drugs (DMARDs) are unsatisfied because of poor therapeutic benefits. The dominance of rheumatoid arthritis globally, the launch of novel therapeutic agents, and favorable reimbursement policies for high-cost treatment products are the factors that boost the growth of global arthritis therapeutics market. In 2016, the International Federation of Psoriasis Association (IFPA) states that more than 125 Mn people were affected with psoriasis. It is estimated that between 11% and 32% of patients with psoriasis incline to develop psoriatic arthritis. Furthermore, nearly 52.2 million adults suffered from arthritis in U.S. alone in 2015. Developments in diagnostics and healthcare infrastructure in developing countries are projected to witness an increased number of diagnosed patients.

Manufacturers in the Arthritis Therapeutic are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.

Global Arthritis Therapeutic Market Segmentation AnalysisBy Arthritis Therapeutic Market is segmented into Psoriatic Arthritis, Rheumatoid Arthritis, Osteoarthritis, Gout and Others. Rheumatoid Arthritis and Psoriatic Arthritis segment is expected to exhibit highest global market share at a CAGR of xx% over forecast period. Increasing occurrence of arthritis diseases globally, is likely to drive key players to develop novel therapeutics treatment for the disease. Strong research and development by key companies supported by huge investments is projected to drive the global arthritis therapeutics market. In 2018, according to the WHO statistics 9.9 % of men AND 18.1 % of women over the age of 60 suffered from osteoarthritis, symptomatic, worldwide. About 80 % of those with osteoarthritis have limitations in movement, and 25 % of women over the age of 60 suffered from symptomatic osteoarthritis, globally.

Global Arthritis Therapeutic Market Regional AnalysisThe Global Arthritis Therapeutic Market has been classified into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East Africa. North America dominated the global arthritis therapeutics market, followed by Europe. Because of a large patient pool suffering from arthritis diseases, like osteoarthritis, rheumatoid arthritis and other conditions. Advantageous reimbursement policies, launching of novel biologics drugs, well-defined regulatory framework, and availability of biosimilars are boost up the market growth in the region. Furthermore, the presence of key players in the region and a strong product pipeline for arthritis treatment are projected to drive the arthritis therapeutics market in the region. This can be ascribed to awareness about arthritis, presence of key players, growing patient pool, favorable reimbursement policies, and availability of biosimilar and biologics arthritis drugs in the region.

The objective of the report is to present comprehensive analysis of Global Arthritis Therapeutic Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding Global Arthritis Therapeutic Market dynamics, structure by analyzing the market segments, and project the Global Arthritis Therapeutic Market size. Clear representation of competitive analysis of key players by Arthritis Therapeutic Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Arthritis Therapeutic Market make the report investors guide.Scope of the Global Arthritis Therapeutic Market

Global Arthritis Therapeutic Market, by Type

Psoriatic Arthritis Rheumatoid Arthritis Osteoarthritis Gout OthersGlobal Arthritis Therapeutic Market, by Drug Class

TNF Inhibitors Interleukin Inhibitors NSAIDs Corticosteroids Xanthine Oxidase Inhibitors OthersGlobal Arthritis Therapeutic Market by Route of Administration

Oral Parenteral TopicalGlobal Arthritis Therapeutic Market, by Distribution Channel

Hospital Pharmacies Retail Pharmacies Online PharmaciesGlobal Arthritis Therapeutic Market, by Region

Asia Pacific North America Europe Latin America Middle East AfricaGlobal Arthritis Therapeutic Market, Major Players

Pfizer Inc. Bristol Myers Squibb Abbvie Inc. Astrazeneca Pharma Ucb Pharma Genentech Janssen Pharmaceutical Immunex Corp. Medac Pharma Boehringer Ingelheim Novartis, Biogen Eli Lilly And Company Astellas Pharma Mallinckrodt Roche Vertex Pharmaceutical

Browse Full Report with Facts and Figures Report at:https://www.maximizemarketresearch.com/market-report/global-arthritis-therapeutic-market/36112/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: [emailprotected]

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

Continued here:
Global Arthritis Therapeutic Market: Industry Analysis and forecast (2019 to 2026) - Galus Australis

Read More...

Rheumatoid Arthritis Therapeutics Market : Opportunities, Demand and Forecasts, 2020-2028 – StartupNG

Monday, August 31st, 2020

Rheumatoid Arthritis Therapeutics Market Scenario 2020-2028:

The analysis of the market provides the global market dynamics and trends of the Rheumatoid Arthritis Therapeutics Market. The market study offers current and future outlook of the Rheumatoid Arthritis Therapeutics Market over the forecast period.

The analysis of the market provides an exhaustive overview with detailed growth scenarios and market potential with accurate market drivers and maximum forecast precision. The report comprises of exclusive and important factors that are likely to have a major impact on the Rheumatoid Arthritis Therapeutics Market throughout the forecast period. This study of the market includes a thorough and considerable amount of addition, which will help new entrants in the most comprehensive manner for better understanding. Click here to get sample of the premium report: https://www.quincemarketinsights.com/request-sample-68410?utm_source= SNG/KK

The analysis of the market commences with the executive summary of the Rheumatoid Arthritis Therapeutics Market study, which includes key findings and key information on the market. It includes market value share for the foremost segments in the Rheumatoid Arthritis Therapeutics Market. In addition, this section includes demand-side trends, supply-side trends, and recommendations for the Rheumatoid Arthritis Therapeutics Market.

Market Segmentation-

Based on the study the Rheumatoid Arthritis Therapeutics Market is segmented by By Molecule Type (Biopharmaceuticals (Biologics, Biosimilars), Pharmaceuticals), By Sales Channel (Prescription, OTC) This information can lead to a focused approach leading to better opportunities being found.

Based on the region, the Rheumatoid Arthritis Therapeutics Market has been categorized into North America, Europe, Asia Pacific, Middle East, and the Rest of the world. It also consists of detailed information regarding developments, key market trends, and market analysis in the Rheumatoid Arthritis Therapeutics Market based on region. The North America and Western Europe regions are estimated to register a stable demand during the forecast period with market recovery from recent slowdowns.

North America region includes the US, Canada, and Mexico. The US is estimated to dominate this market with a sizeable share followed by Canada, and Mexico. The industrial sector is a major contributor to the US and Canada economies overall. Hence, the supply of advanced materials in production activities is critical to the overall growth of industries in this region.

Get ToC for the overview of the premium report https://www.quincemarketinsights.com/request-toc-68410?utm_source=SNG/KK

The Rheumatoid Arthritis Therapeutics Market report examines the potential of the market in the key geographical region:

Speak to analyst before buying this report https://www.quincemarketinsights.com/enquiry-before-buying-68410?utm_source=SNG/KK

Competitive Analysis

The report includes a comprehensive list of all the leading manufacturers in the Rheumatoid Arthritis Therapeutics Market, along with detailed information about each company, which includes the company overview, revenue share, strategic overview, and recent company developments. Market players featured in this report include AbbVie;Boehringer Ingelheim GmbH;Novartis AG; Regeneron Pharmaceuticals, Inc.;Pfizer, Inc.; Bristol-Myers Squibb Company;F. Hoffmann-La Roche Ltd.;UCB S.A.; Johnson & Johnson Services, Inc.; andAmgen, Inc.. A detailed view of the competitive landscape covers future capabilities, key mergers & acquisitions, new product releases, new product innovations, etc.

Reasons why you should buy this report:

ABOUT US:

QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact:Quince Market Insights

Office No- A109

Pune, Maharashtra 411028

Phone: APAC +91 706 672 4848 / US +1 208 405 2835 / UK +44 1444 39 0986

Email: [emailprotected]

Web: https://www.quincemarketinsights.com

View original post here:
Rheumatoid Arthritis Therapeutics Market : Opportunities, Demand and Forecasts, 2020-2028 - StartupNG

Read More...

Arrow Organics Commits to Science Based Full Spectrum Blends By Partnering with Ivy League Scientist – PRNewswire

Monday, August 31st, 2020

LOS ANGELES, Aug. 31, 2020 /PRNewswire/ -- Arrow Organics offers a wide range of premium CBD products. In an industry full of new competition and subpar transparency, Arrow Organics doubled down on science based CBD by pairing up with Alex Laughlin, a Biology PhD candidate from Cornell University. "After reviewing countless scientific case studies on CBD's efficacy in helping arthritis pains and sports injuries, we sought out the help of Alex Laughlin, MSc to carefully choose which formulas would give our customers the best relief," said Luke Paschal, CEO of Arrow Organics.

Arrow Organics recently launched two new topical CBD rubs formulated to provide relief from sore and injured muscles and joints by reducing inflammation to affected areas. "The ingredients in both the Intensive Relief Rub and Athletic Freeze Rub were specifically chosen for their ability to ease arthritis pain and muscle aches. "Coupling CBD's powerful effects with the specific ingredients of both creams have been shown to greatly reduce pain in various forms," said Laughlin.

Slow moving regulation hands the responsibility off to consumers on choosing the correct CBD company. The consumer must be educated on what types of CBD they're buying, if the lab reports are consistent with labeling, and how to properly use CBD. You can visit Arrow Organics website to view lab reports and get educated on CBD. "We happily welcome any questions about CBD, please feel free to reach out through our website or through email ([emailprotected])" Paschal.

Arrow Organics is currently offering free shipping nationwide as well as 20% off your next order with code "ARROW20".

Photo(s):https://www.prlog.org/12836149

Press release distributed by PRLog

SOURCE Arrow Organics

Read the original here:
Arrow Organics Commits to Science Based Full Spectrum Blends By Partnering with Ivy League Scientist - PRNewswire

Read More...

Page 19«..10..18192021..3040..»


2024 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick